Structured Benefit–risk assessment: a review of key publications and initiatives on frameworks and methodologies
暂无分享,去创建一个
Shahrul Mt-Isa | Alexander Schacht | Mario Ouwens | Martin Gebel | S. Mt-Isa | M. Ouwens | A. Schacht | I. Hirsch | Veronique Robert | Ian Hirsch | M. Gebel | V. Robert
[1] L. Phillips,et al. Review of visualisation methods for therepresentation of benefit-risk assessment ofmedication: stage 2 of 2 , 2013 .
[2] Rebecca Noel,et al. Application of the Benefit-Risk Action Team (BRAT) Framework in Pharmaceutical R&D: Results From a Pilot Program , 2012 .
[3] Richard W. Marklin,et al. Case Study Report , 2008, Journal of occupational and environmental hygiene.
[4] Jixian Wang,et al. A review of risk measures in pharmacoepidemiology with tips for statisticians in the pharmaceutical industry , 2011, Pharmaceutical statistics.
[5] Shahrul Mt-Isa,et al. IMI-PROTECT benefit-risk grouprecommendations report:recommendations for the methodology andvisualisation techniques to be used in theassessment of benefit and risk of medicines , 2014 .
[6] R. Varadhan,et al. A framework for organizing and selecting quantitative approaches for benefit-harm assessment , 2012, BMC Medical Research Methodology.
[7] S. Walker,et al. Progress on the Development of a Benefit / Risk Framework for Evaluating Medicines , 2010 .
[8] Allan Wailoo,et al. Using health state utility values in models exploring the cost-effectiveness of health technologies. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[9] B S Levitan,et al. Application of the BRAT Framework to Case Studies: Observations and Insights , 2011, Clinical pharmacology and therapeutics.
[10] Constantine Gatsonis,et al. The promise and realities of comparative effectiveness research , 2010, Statistics in medicine.
[11] Lawrence D. Phillips,et al. Evaluating benefit-risk: an Agency perspective , 2012 .
[12] John Doyle,et al. A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[13] B S Levitan,et al. Development of a Framework for Enhancing the Transparency, Reproducibility and Communication of the Benefit–Risk Balance of Medicines , 2011, Clinical pharmacology and therapeutics.
[14] Louis P Garrison,et al. Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. , 2007, Health affairs.
[15] Robin Gregory,et al. Exploring a structured decision approach as a means of fostering participatory space policy making at NASA , 2002 .
[16] Donna Rowen,et al. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[17] Lawrence D. Phillips,et al. Benefit-risk methodology project:work package 1 report: description of the current practice of benefit-risk assessment for centralised procedure products in the EU regulatory network , 2011 .
[18] Nan Wang,et al. Benefit–risk assessment in a post‐market setting: a case study integrating real‐life experience into benefit–risk methodology , 2014, Pharmacoepidemiology and drug safety.
[19] H. Eichler,et al. Safe drugs and the cost of good intentions. , 2009, The New England journal of medicine.
[20] S. Walker,et al. Is there a need for a universal benefit–risk assessment framework for medicines? Regulatory and industry perspectives , 2013, Pharmacoepidemiology and drug safety.
[21] L. Phillips,et al. Balancing benefit and risk of medicines: a systematic review and classification of available methodologies , 2014, Pharmacoepidemiology and drug safety.
[22] M. Buxton,et al. Prioritisation of health technology assessment. The PATHS model: methods and case studies. , 2003, Health technology assessment.